Natera Inc

25 Sept 2026, 19:46 UTC

RBC Capital raised its price target on Natera Inc to $460, maintaining an Outperform rating, as shares trade modestly higher amid strong market position.

24 Sept 2026, 23:01 UTC

Natera Inc is trading modestly lower in after-market hours, having retraced from an early gain and reflecting a cumulative decline since Thursday's close.

22 Sept 2026, 20:02 UTC

Natera Inc's Signatera test received regulatory approval in Japan as a companion diagnostic for muscle-invasive bladder cancer, driving the stock sharply higher.

21 Sept 2026, 22:11 UTC

Natera Inc is trading modestly higher in after-market hours, remaining well above its 20-day moving average following a peak earlier in the session.

18 Sept 2026, 22:31 UTC

Natera Inc declined in after-market trading, moving lower since Friday's close, despite previously trading above its 20-day moving average.

17 Sept 2026, 23:06 UTC

Natera Inc's shares traded flat in after-market hours, remaining 10.18% above the 20-day moving average amid positive economic indicators.

16 Sept 2026, 19:07 UTC

Natera Inc shares fell modestly lower, reaching a notable low today, though remaining above their 20-day moving average.

15 Sept 2026, 23:01 UTC

Natera Inc shares are higher in after-market hours following Tuesday's close, continuing a trend of four consecutive sessions that also closed higher.

14 Sept 2026, 19:26 UTC

Natera Inc is gaining momentum as it breaks above September's value area. UBS raised its price target while maintaining a "buy" rating.

11 Sept 2026, 22:51 UTC

Natera Inc shares are lower in after-market hours, with no specific news identified to explain the movement. Broader market sentiment may be influencing trading.

9 Sept 2026, 20:07 UTC

UBS has raised its price target on Natera Inc. to $435, maintaining a Buy rating and contributing to a rise in shares during Wednesday's session.

8 Sept 2026, 23:06 UTC

Natera Inc. shares are higher in after-market trading, maintaining upward momentum since Tuesday's close despite an earlier pullback. The stock is above its 20-day moving average.

3 Sept 2026, 19:36 UTC

Baird raised Natera's price target to $376 from $348, maintaining an Outperform rating. Shares are higher since Wednesday's close amid easing interest rate concerns.

2 Sept 2026, 23:26 UTC

Natera Inc. shares are higher in after-market trading, continuing a strong performance over the past month, well above the 20-day moving average.

1 Sept 2026, 19:36 UTC

Natera's Signatera test shows 100% predictive value for lymphoma treatment responses, boosting shares higher during Tuesday's session.

31 Aug 2026, 23:01 UTC

Natera Inc shares are higher in after-market trading, stabilizing near earlier highs amid broader economic concerns over potential interest rate hikes.

28 Aug 2026, 20:02 UTC

Natera Inc partners with Susan G. Komen to enhance breast cancer education. Shares are lower amid high trading volume and broader market pressures.

27 Aug 2026, 20:07 UTC

Natera partners with Angiex to use Signatera in a Phase I trial for AGX101, aimed at enhancing cancer treatment response evaluation. Shares are roughly flat.

26 Aug 2026, 19:26 UTC

Natera Inc's shares are higher today, reflecting a general market uptrend. The stock remains above its 20-day moving average and near a one-month high.

24 Aug 2026, 19:46 UTC

Natera Inc shares are lower today, pulling back from earlier session highs. Rising oil prices and geopolitical tensions impact overall market sentiment.

21 Aug 2026, 20:06 UTC

Natera Inc shares are higher today, rebounding from an early dip amid positive momentum in the biotechnology sector and overall market performance.

20 Aug 2026, 23:16 UTC

Natera Inc. shares are slightly higher in after-market hours, remaining near the upper end of their one-month range amid broader market pressure from rising yields.

19 Aug 2026, 20:02 UTC

Natera Inc shares are higher today amid a broader market rally, with notably increased trading volume indicating heightened investor interest.

18 Aug 2026, 23:36 UTC

Natera Inc shares are lower in after-market hours, with no specific news identified. Broader market sentiment is impacted by declines in the Nikkei 225 Index.

17 Aug 2026, 19:36 UTC

Natera Inc reports second-quarter revenue of $752.8 million, exceeding expectations. Shares are higher as the company cites strong test volume growth and regulatory approvals.

13 Aug 2026, 19:26 UTC

Natera Inc is trading lower despite announcing a collaboration on a Phase 1 clinical trial and exceeding second-quarter expectations by $100 million.

12 Aug 2026, 20:06 UTC

Natera Inc shares are rising after analyst upgrades and support for a Phase 1 trial in Germany using its Latitude assay to monitor tumor DNA.

11 Aug 2026, 20:02 UTC

Natera Inc reported strong Q2 revenue of $752.8 million but shares are lower amid concerns over significant insider selling.

10 Aug 2026, 20:02 UTC

Natera Inc shares are lower amid negative sentiment from insider selling, despite recent analyst upgrades and price target increases from Morgan Stanley and Barclays.

7 Aug 2026, 20:03 UTC

Natera Inc. shares rise sharply after analyst upgrades and strong earnings. RBC Capital raised its price target to $350, citing robust revenue growth.